Jason Cohen

About the Author Jason Cohen

Jason is a Smarter Analyst editor and writer, who specializes in biotech and cannabis-based pharmaceutical companies.

TherapeuticsMD (TXMD) Stock Has Triple-Digit Upside From Here, Says Analyst

TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …

Here’s Why This Analyst Doubled His Price Target on New Age Beverages (NBEV) Stock

After seeing struggles in 2018, marijuana stocks are back in the limelight. With new legalization efforts taking place and the evolution of the …

Should You Pull the Trigger on Aphria (APHA) Stock? This Analyst Says Yes, But Be Cautious

Whether you realize it or not, the cannabis industry had an incredible year in 2018. You might not think this was the case, …

Amarin (AMRN): Management Is Flying in the Dark

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …

Aurora Cannabis (ACB): Analyst Sees Limited Upside for the Cannabis Stock

Last week, Aurora Cannabis (ACB) became the first cannabis stock to issue sales guidance in a postlegalization environment. Unfortunately, the company’s preliminary fiscal …

Kitov Pharma (KTOV): Investors Are Taking Some Profits Off the Table, Stock Tumbles 20%

What a wild ride it’s been for Kitov Pharma (KTOV). After skyrocketing nearly 170% in Tuesday’s trading session, shares of the pharmaceutical firm …

Tilray (TLRY) Stock Rallies Over Lock-Up Expiration Saga

Tilray (TLRY) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 22% upturn. Why …

Here’s Why Amarin (AMRN) Stock Soared Today

Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …

Catalyst Pharmaceuticals (CPRX) Stock Receives Upbeat Wall Street Comments

Catalyst Pharmaceuticals (CPRX) hosted a conference call yesterday to discuss its commercialization plan for the company’s newly FDA-approved LEMS drug, Firdapse. Catalyst announced …

Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts